Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Zacks.com on MSN1d
Equifax (EFX) Earnings Expected to Grow: Should You Buy?Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
clinicaltrialsarena on MSN3d
Akero’s cirrhosis treatment shows promise in Phase IIb studyAkero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback